Obstacles to Deprescribing Among French Patients Over 75 Years of Age Treated in the Geriatric Hospital Network

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-01

Study Completion Date

2023-01-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to highlight action guidelines to encourage acceptance of deprescribing in people over 75 years of age: training, therapeutic education, post-prescription follow-up, specific patient pathways, specific consultations or even the integration of an advanced practice nurse in this process.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Deprescribing Intervention Among Nursing Home Residents With Major Neurocognitive Disorders

NCT05155748

Dementia

COMPLETED NA

Optimization of Drug Prescribing in an Elderly Population of Geriatric Consultations

NCT02740764

Functional Autonomy Level

UNKNOWN NA

Deprescribing for Older Adults After Hospital Discharge in Home Health Care

NCT05630144

Polypharmacy

COMPLETED NA

Deprescribing in a Long Term Care Facility

NCT03091153

Polypharmacy

COMPLETED NA

Reducing Post-discharge Adverse Drug Events Amongst the Elderly: a Multi-centre Electronic Deprescribing Intervention

NCT03272607

Adverse Drug Event

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For several years now, the proportion of senior citizens in our country has been rising steadily. There are now 6.4 million people over the age of 75 in France.

It is therefore important to take into account the needs and specificities of this part of the population. One of its particularities is polypathology. Indeed, from the age of 70 onwards, 93% of elderly subjects have at least 2 diseases and 85% have at least 3. This polypathology will lead to a large number of different prescribers with an increased risk of having more than 5 molecules in their personal treatment. This is known as polypharmacy.

In the elderly, polypharmacy is harmful. It increases the risk of adverse effects and drug interactions. In France, 20% of patients over 75 years old and 25% of those over 85 years old consult the emergency room because of adverse drug reactions.

The literature shows that we can act on these adverse events by "deprescribing". De-prescribing is defined as intentionally stopping the prescription of an unnecessary or potentially dangerous drug for a patient.

The expected benefit for the patient is to reduce the iatrogenic risks induced by treatments that would no longer be useful for him/her or that have a negative benefit/risk balance. To achieve this objective, the patient must understand this risk, understand the benefit he or she can derive from it and be an actor in this process.

For carers, the expected benefit is greater involvement of the patient in the process, better adherence to the approach, which can be organised and carried out in a safer way.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Medication Abuse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Deprescribing

Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units

self-questionnaire

Intervention Type OTHER

Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

self-questionnaire

Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 75 years and over
* Hospitalized in geriatric short-stay or geriatric rehabilitation units
* Patients who did not object to participation in the study

Exclusion Criteria

* Patient refusal
* Patients not able to understand and fill in the questionnaire: Cognitive disorders, Confusion, Unstable clinical state, Sensory disorders, not speaking French.
* Patient under protective supervision (guardianship or curatorship)

Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No